Use our Whitepapers to Expand Your Knowledge
These top level issues are discussed in our White Papers, leveraging our industry expertise to help customers answer the most challenging preclinical research questions.
With the continued rise of immunotherapeutics, more preclinical research is moving towards using immunocompentent models, which are required to assess immunomodulatory agents. Choosing the correct model from the variety available can be difficult, but is needed to help to efficiently progress novel agents. Download our White Paper to learn which human specific and mouse analogue models are available, and how to select the best model for any given immuno-oncology study.
How to Use CrownBio’s Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation
Target identification and MOA studies are a vital early stage in cancer drug development, and require disease-relevant cell-based platforms, with linked later stage models to accelerate lead compounds. Discover how CrownBio’s integrated oncology portfolio of in vitro, in vivo, and ex vivo products and services help advance target identification and MOA studies within drug discovery programs, allowing go/no-go decisions to be made with confidence.
Human tumor bearing humanized mouse models are needed for the preclinical assessment of human-specific immunotherapeutics. Given the complexity of these models (including hCD34+ and hPBMC mice combined with PDX and traditional xenografts), the key to optimizing their use is to bring together an in depth knowledge of each model features and limitations, with bespoke study designs, centred around the specific question being asked in each study. Download our White Paper to discover different immune system humanization strategies and how these result in models with differing pros and cons, alongside successful model utilization in cancer pharmacology case studies.
New approaches are needed in oncology, to better predict clinical efficacy within preclinical assessment. Mouse Clinical Trials (MCT) using patient-derived xenograft (PDX) models are a highly predictive alternative to traditional drug discovery methods, providing a more clinically relevant situation, a better perspective of patient-to-patient heterogeneity, and a framework for biomarker discovery. Download our White Paper to discover the various types of MCT, and identify which method will best progress any given drug development program.